{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8","value":"75.8"},{"groupId":"OG001","spread":"0.9","value":"75.3"}]}],"title":"Prior to cycle 1 (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"74.2"},{"groupId":"OG001","spread":"0.9","value":"73.4"}]}],"title":"Prior to cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"73.3"},{"groupId":"OG001","spread":"1.0","value":"72.3"}]}],"title":"Prior to cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"77.1"},{"groupId":"OG001","spread":"1.0","value":"77.2"}]}],"title":"6 months post cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"77.0"},{"groupId":"OG001","spread":"1.0","value":"77.8"}]}],"title":"12 months post cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"description":"Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). Each item in the FACT-O TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The FACT-O TOI score ranges 0-100 with a large score suggests better QOL.","dispersionType":"Standard Error","groups":[{"description":"All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis","id":"OG000","title":"Paclitaxel and Carboplatin Chemotherapy"},{"description":"All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis","id":"OG001","title":"Paclitaxel and Carboplatin Chemotherapy With Bevacizumab"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Provided baseline and at least one follow-up assessment (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).","reportingStatus":"POSTED","timeFrame":"1. Prior to cycle 1 (baseline), 2. Prior to cycle 3 (6 weeks post cycle 1), 3. Prior to cycle 6 (15 weeks post cycle 1), 4. 6 months post cycle 1, 5. 12 months post cycle 1.","title":"Patient Reported Quality of Life (Chemotherapy Analysis)","type":"SECONDARY","unitOfMeasure":"score on a scale"}